symbol,synonyms,gene_locus,gene_id,transcript_id,conservation,conservation_ortholog,conservation_species,biological_context,context_detail,tissue/cell line,genome_variation,variation_detail,epigenetic_modification,modification_detail,expression,expression_detail,regulator_type,regulator,regulator_interaction,regulator_effect,target_type,target,target_interaction,target_effect,experimental_method,molecular_function,biological_process,pathway,functional_mechanism,clinical_detail,drug,description,pmid
ADARB2-AS1,bA466B20.1;C10orf109;NCRNA00168,10p15.3,HSALNG0075559,"HSALNT0157365,HSALNT0157367,HSALNT0157368,HSALNT0157369,HSALNT0157370,HSALNT0157371,HSALNT0157372,HSALNT0289522,HSALNT0355598,HSALNT0355599,HSALNT0355600,HSALNT0355601,HSALNT0355602,HSALNT0355603,HSALNT0355604",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg19976363,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
ADD3-AS1,,10q25.1,HSALNG0080557,"HSALNT0168002,HSALNT0168003,HSALNT0168004,HSALNT0168005,HSALNT0359946,HSALNT0359947,HSALNT0359948,HSALNT0359949,HSALNT0359950,HSALNT0359951,HSALNT0359952,HSALNT0359953,HSALNT0359954,HSALNT0359955,HSALNT0359956",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg10646968;cg18516365,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
AGAP2-AS1,PUNISHER,,,,,NA,,Disease,Atherosclerosis,HA-VSMC;artery,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,"Protein,miRNA",AGO2;miR-664a-5p,"Protein-RNA,RNA-RNA","Promote,Inhibit",NA,Mitochondrial Fission Regulation,Apoptosis,NA,ceRNA,NA,H2O2 treatment,,35663194
BGLT3,LINC01083;BGL3;lncRNA-BGL3,11p15.4,HSALNG0082362,"HSALNT0171402,HSALNT0288894,HSALNT0409632",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg26078436,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
CASC7,,,,,,NA,,Disease,Atherosclerosis,Artery,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,miRNA,miR-21,RNA-RNA,Inhibit,NA,NA,NA,Nf-κb signaling pathway,ceRNA,NA,NA,,34887360
CCDC26,MGC27434;RAM,8q24.21,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg16675872,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Differentially expressed,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,Cancer proliferation,NA,NA,NA,NA,"9p21.3 may promote atherosclerosis by regulating expression of anril,which in turn is associated with altered expression of genes controlling cellular proliferation pathways.",19592466
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Differentially expressed,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,Transcripts eu741058 and nr_003529 of antisense noncoding rna in the ink4 locus (anril) were significantly increased in carriers of the risk haplotype.Anril expression is associated with atherosclerosis risk.Expression of anril transcripts was directly correlated with severity of atherosclerosis.,20056914
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Differentially expressed,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,Anril dq485454 which is not genetically determined by the 9p21 genotype was significantly correlated with mtap expression.Abundantly expressed in atherosclerotic lesions.,20637465
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,"While the exact role of anril awaited further elucidation,common disease genomewide association studies (gwas) have surprisingly identified the anril gene as a genetic susceptibility locus shared associated by coronary disease,intracranial aneurysm and also type 2 diabetes.",20956613
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,SNP,NA,NA,NA,RNA,Differentially expressed,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,Gene expression studies have found that expression levels of cdkn2a/cdkn2b/anril are co-regulated and associated with the risk haplotype and atherosclerosis severity.,21550161
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,Cancer proliferation,NA,NA,NA,NA,"Genome-wide association studies (gwas) have identified genetic variants contributing to the risk of cardiovascular disease (cvd) at the chromosome 9p21 locus.The cvd-associated region is adjacent to the two cyclin dependent kinase inhibitors (cdkn)2a and 2b and the last exons of the non-coding rna,anril.Cdkn2a/b and anril (exons 1-2 and 17-18) expression was measured employing rt-pcr.Overall,our results suggest that several cvd-associated snps in the 9p21 locus affect the expression of anril,which,in turn modulate cell growth,possibly via cdkn2a/b regulation.",22178423
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,Genetic variation in lncRNA genes causes disease and influences susceptibility.,23791884
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Differentially expressed,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,NA,NA,NA,NA,NA,"The large non-coding rna anril,which is associated with atherosclerosis,periodontitis and several forms of cancer,regulates adipor1,vamp3 and c11orf10.",23813974
CDKN2B-AS1,ANRIL;RP11-145E5.4;NCRNA00089;p15AS;CDKN2B-AS;PCAT12;CDKN2BAS,9p21.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Array;Genotyping,NA,Cancer proliferation,NA,NA,NA,NA,Chr9p21 encodes the long non-coding rna (ncrna) antisense non-coding rna in the ink4 locus (anril).Anril expression is associated with the chr9p21 genotype and correlated with atherosclerosis severity.,23861667
CLRN1-AS1,UCRP;CLRN1OS,3q25.1,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg24721964,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28698603
COX10-AS1,COX10AS;COX10-AS,17p12,HSALNG0114686,"HSALNT0237444,HSALNT0237446,HSALNT0237449,HSALNT0237450,HSALNT0237452,HSALNT0237453,HSALNT0237455,HSALNT0237461,HSALNT0237465,HSALNT0237480,HSALNT0237481,HSALNT0237482,HSALNT0237484,HSALNT0237485,HSALNT0388564,HSALNT0388565,HSALNT0388566,HSALNT0388567,HSALNT0388568,HSALNT0388569,HSALNT0388570,HSALNT0388571,HSALNT0388572,HSALNT0388573,HSALNT0388574,HSALNT0388575,HSALNT0388576,HSALNT0388577,HSALNT0388578,HSALNT0388580,HSALNT0388581,HSALNT0388582,HSALNT0388583,HSALNT0388584,HSALNT0388585,HSALNT0388586,HSALNT0388587,HSALNT0388588,HSALNT0388589,HSALNT0388590,HSALNT0388591,HSALNT0388592,HSALNT0388593,HSALNT0388594,HSALNT0388595,HSALNT0388596,HSALNT0388597,HSALNT0388601,HSALNT0388602,HSALNT0388603,HSALNT0388604,HSALNT0388605,HSALNT0388606,HSALNT0388607,HSALNT0388608",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg08898866;cg27621897,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
CTBP1-AS,PCAT10,4p16.3,HSALNG0141602,HSALNT0289491,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg07928191,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
CYP1B1-AS1,MGC34824;C2orf58,2p22.2,HSALNG0014289,"HSALNT0030190,HSALNT0030191,HSALNT0030192,HSALNT0030195,HSALNT0030196,HSALNT0030198,HSALNT0030199,HSALNT0030201,HSALNT0030207,HSALNT0030208,HSALNT0030209,HSALNT0030210,HSALNT0030211,HSALNT0030213,HSALNT0030215,HSALNT0030216,HSALNT0030218,HSALNT0030220,HSALNT0030222,HSALNT0030224,HSALNT0030225,HSALNT0030227,HSALNT0030229,HSALNT0030231,HSALNT0030233,HSALNT0030235,HSALNT0030237,HSALNT0030239,HSALNT0030241,HSALNT0030242,HSALNT0030245,HSALNT0030246,HSALNT0030249,HSALNT0030250,HSALNT0030251,HSALNT0030253,HSALNT0030255,HSALNT0030257,HSALNT0030259,HSALNT0030261,HSALNT0030262,HSALNT0030279,HSALNT0030284,HSALNT0301780,HSALNT0301781,HSALNT0301782,HSALNT0301783,HSALNT0301784,HSALNT0301785,HSALNT0301786,HSALNT0301787,HSALNT0301788,HSALNT0301789,HSALNT0301790,HSALNT0301791,HSALNT0301794,HSALNT0301795,HSALNT0301796,HSALNT0301802,HSALNT0301803,HSALNT0301813",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg10481134,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
DSCR4,DCRB,21q22.13,HSALNG0147182,"HSALNT0404090,HSALNT0404091,HSALNT0404092,HSALNT0404093",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg13538551,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
DSCR8,MTAG2;CT25.1a;CT25.1b;MMA-1a;MMA-1b;C21orf65,21q22.13,HSALNG0133055,"HSALNT0273457,HSALNT0273458,HSALNT0273459,HSALNT0273460,HSALNT0273461,HSALNT0273462,HSALNT0273481,HSALNT0273483,HSALNT0273486,HSALNT0289479,HSALNT0404094,HSALNT0404095,HSALNT0404096,HSALNT0404097,HSALNT0404098,HSALNT0404099,HSALNT0404100,HSALNT0404101,HSALNT0404102,HSALNT0404103,HSALNT0404104,HSALNT0404105,HSALNT0404106,HSALNT0404107",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg13538551,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
FAM167A-AS1,C8orf12,8p23.1,HSALNG0063438,"HSALNT0133074,HSALNT0133077,HSALNT0133079,HSALNT0345224,HSALNT0345225,HSALNT0345226",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg05445291,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
GAS5,SNHG2;NCRNA00030,1q25.1,HSALNG0008545,"HSALNT0017659,HSALNT0017660,HSALNT0017661,HSALNT0017663,HSALNT0017666,HSALNT0017667,HSALNT0017670,HSALNT0017671,HSALNT0017679,HSALNT0017696,HSALNT0017697,HSALNT0017700,HSALNT0017701,HSALNT0017702,HSALNT0017703,HSALNT0017704,HSALNT0017705,HSALNT0017706,HSALNT0017716,HSALNT0017717,HSALNT0017719,HSALNT0017720,HSALNT0017721,HSALNT0017722,HSALNT0017723,HSALNT0017724,HSALNT0017725,HSALNT0017726,HSALNT0017728,HSALNT0017732,HSALNT0017737,HSALNT0017738,HSALNT0017739,HSALNT0017740,HSALNT0017744,HSALNT0017748,HSALNT0017749,HSALNT0017751,HSALNT0017753,HSALNT0017757,HSALNT0017760,HSALNT0017768,HSALNT0017773,HSALNT0017776,HSALNT0017777,HSALNT0296610,HSALNT0296611,HSALNT0296612,HSALNT0296613,HSALNT0296614,HSALNT0296615,HSALNT0296616,HSALNT0296617,HSALNT0296619,HSALNT0296620,HSALNT0296621,HSALNT0296622,HSALNT0296623,HSALNT0296624,HSALNT0296625,HSALNT0296626,HSALNT0296627,HSALNT0296628,HSALNT0296629,HSALNT0296630,HSALNT0296631,HSALNT0296632,HSALNT0296633,HSALNT0296634,HSALNT0296635,HSALNT0296636,HSALNT0296637,HSALNT0296638,HSALNT0296639,HSALNT0296640,HSALNT0296641,HSALNT0296642,HSALNT0296643,HSALNT0296644,HSALNT0296645,HSALNT0296646",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,PDCD4,NA,Promote,Q-RCR;Wetern blotting assay;Luciferase reporter assay,NA,Evading apoptosis;Cancer proliferation;Apoptosis;Insensitivity to antigrowth signals,NA,ceRNA,NA,NA,"Association between the deletion allele of ins/del polymorphism (rs145204276) in the promoter region of gas5 with the risk of atherosclerosis.Gas5 directly targets mir-21 and functions as a competing endogenous rna to suppress mir-21 expression.Gas5 positively regulated pdcd4 expression via inhibiting mir-21 expression.In summary,rs145204276 was associated with the risk of atherosclerosis by affecting the proliferation and apoptosis of endothelial cells via regulating the gas5/mir-21/pdcd4 signaling pathway.",30205366
GAS5,SNHG2;NCRNA00030,1q25.1,HSALNG0008545,"HSALNT0017659,HSALNT0017660,HSALNT0017661,HSALNT0017663,HSALNT0017666,HSALNT0017667,HSALNT0017670,HSALNT0017671,HSALNT0017679,HSALNT0017696,HSALNT0017697,HSALNT0017700,HSALNT0017701,HSALNT0017702,HSALNT0017703,HSALNT0017704,HSALNT0017705,HSALNT0017706,HSALNT0017716,HSALNT0017717,HSALNT0017719,HSALNT0017720,HSALNT0017721,HSALNT0017722,HSALNT0017723,HSALNT0017724,HSALNT0017725,HSALNT0017726,HSALNT0017728,HSALNT0017732,HSALNT0017737,HSALNT0017738,HSALNT0017739,HSALNT0017740,HSALNT0017744,HSALNT0017748,HSALNT0017749,HSALNT0017751,HSALNT0017753,HSALNT0017757,HSALNT0017760,HSALNT0017768,HSALNT0017773,HSALNT0017776,HSALNT0017777,HSALNT0296610,HSALNT0296611,HSALNT0296612,HSALNT0296613,HSALNT0296614,HSALNT0296615,HSALNT0296616,HSALNT0296617,HSALNT0296619,HSALNT0296620,HSALNT0296621,HSALNT0296622,HSALNT0296623,HSALNT0296624,HSALNT0296625,HSALNT0296626,HSALNT0296627,HSALNT0296628,HSALNT0296629,HSALNT0296630,HSALNT0296631,HSALNT0296632,HSALNT0296633,HSALNT0296634,HSALNT0296635,HSALNT0296636,HSALNT0296637,HSALNT0296638,HSALNT0296639,HSALNT0296640,HSALNT0296641,HSALNT0296642,HSALNT0296643,HSALNT0296644,HSALNT0296645,HSALNT0296646",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-26a,RNA-RNA,NA,Rip;QRT-PCR;Luciferase reporter assay;Rna pull-down assay,NA,Autophagy;Evading apoptosis;Apoptosis,NA,ceRNA,NA,NA,"Knockdown of growth-arrest specific transcript 5 restores oxidized low-density lipoprotein-induced impaired autophagy flux via upregulating mir-26a in human endothelial cells.We further demonstrated that gas5 directly bound to mir-26a in haecs.Gas5 knockdown inhibited cell apoptosis and activated autophagy flux,whereas inhibition of mir-26a reversed the effect of gas5 in haecs.",30468731
H19,D11S813E;ASM;ASM1;NCRNA00008;LINC00008;MIR675HG,11p15.5,HSALNG0082178,"HSALNT0171121,HSALNT0171122,HSALNT0171123,HSALNT0171124,HSALNT0171125,HSALNT0289462,HSALNT0361012,HSALNT0361013,HSALNT0361014,HSALNT0361015,HSALNT0361016,HSALNT0361017,HSALNT0361018,HSALNT0361019,HSALNT0361020,HSALNT0361021,HSALNT0361022,HSALNT0361023,HSALNT0361024,HSALNT0361025,HSALNT0361026,HSALNT0361027,HSALNT0361028,HSALNT0361029,HSALNT0361030,HSALNT0361031",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,CPG methylation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Microarray,NA,NA,NA,NA,NA,NA,The most pronounced differences of atherosclerotic plaques in dna methylation levels were registered for a site which is located in cpg-island of imprinted gene h19.,21954592
H19,D11S813E;ASM;ASM1;NCRNA00008;LINC00008;MIR675HG,11p15.5,HSALNG0082178,"HSALNT0171121,HSALNT0171122,HSALNT0171123,HSALNT0171124,HSALNT0171125,HSALNT0289462,HSALNT0361012,HSALNT0361013,HSALNT0361014,HSALNT0361015,HSALNT0361016,HSALNT0361017,HSALNT0361018,HSALNT0361019,HSALNT0361020,HSALNT0361021,HSALNT0361022,HSALNT0361023,HSALNT0361024,HSALNT0361025,HSALNT0361026,HSALNT0361027,HSALNT0361028,HSALNT0361029,HSALNT0361030,HSALNT0361031",,NA,,Disease,atherosclerosis,Blood,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR;Wetern blotting assay,NA,NA,NA,NA,NA,NA,"Compared with the normal healthy people,the expression of h19 was higher in patients with atherosclerosis.",28165553
H19,D11S813E;ASM;ASM1;NCRNA00008;LINC00008;MIR675HG,11p15.5,HSALNG0082178,"HSALNT0171121,HSALNT0171122,HSALNT0171123,HSALNT0171124,HSALNT0171125,HSALNT0289462,HSALNT0361012,HSALNT0361013,HSALNT0361014,HSALNT0361015,HSALNT0361016,HSALNT0361017,HSALNT0361018,HSALNT0361019,HSALNT0361020,HSALNT0361021,HSALNT0361022,HSALNT0361023,HSALNT0361024,HSALNT0361025,HSALNT0361026,HSALNT0361027,HSALNT0361028,HSALNT0361029,HSALNT0361030,HSALNT0361031",,NA,,Disease,atherosclerosis,Blood;Raw264.7,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-130b,RNA-RNA,NA,Q-RCR;Wetern blotting assay;Luciferase reporter assay,NA,Inflammatory response;Adipogenesis,NA,ceRNA,NA,NA,LncRNA h19 abolished the facilitating effect of mir-130b inhibitor on adipogenesis and inflammation response by up-regulating the expression of mir-130b.Silencing of h19 inhibits the adipogenesis and inflammation response in ox-ldl-treated raw264.7 cells by up-regulating mir-130b.The adding of lncRNA h19 abolished the facilitating effect of mir-130b inhibitor on adipogenesis and inflammation response by up-regulating the expression of mir-130b.The bioinformatic analysisshowed that there existed complementary site of mir-130b in h19 rNA.,29172088
H19,D11S813E;ASM;ASM1;NCRNA00008;LINC00008;MIR675HG,11p15.5,HSALNG0082178,"HSALNT0171121,HSALNT0171122,HSALNT0171123,HSALNT0171124,HSALNT0171125,HSALNT0289462,HSALNT0361012,HSALNT0361013,HSALNT0361014,HSALNT0361015,HSALNT0361016,HSALNT0361017,HSALNT0361018,HSALNT0361019,HSALNT0361020,HSALNT0361021,HSALNT0361022,HSALNT0361023,HSALNT0361024,HSALNT0361025,HSALNT0361026,HSALNT0361027,HSALNT0361028,HSALNT0361029,HSALNT0361030,HSALNT0361031",,NA,,Disease,atherosclerosis,Muscle,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG;NA,WNT1;miR-148b,NA;NA,promote;NA,Rip;Q-RCR;Luciferase reporter assay,NA,Evading apoptosis;Cancer proliferation;Apoptosis;Insensitivity to antigrowth signals,NA,ceRNA,NA,NA,"H19 knockdown suppresses proliferation and induces apoptosis by regulating mir-148b/wnt/beta-catenin in ox-ldl-stimulated vascular smooth muscle cells.H19 inhibited mir-148b expression by direct interaction.Further mechanical explorations showed that wnt1 was a target of mir-148b and h19 acted as a competing endogenous rna (cerna) of mir-148b to enhance wnt1 expression.H19 facilitated proliferation and inhibited apoptosis through modulating wnt/beta-catenin signaling pathway via mir-148b in ox-ldl-stimulated ha-vsmcs,implicating the potential values of h19 in as therapy.H19 knockdown suppressed proliferation and promoted apoptosis in ha-vsmcs following the treatment of ox-ldl.H19 inhibited mir-148b expression by direct interaction.",29415742
HAND2-AS1,DEIN;FLJ11539;NBLA00301,4q34.1,HSALNG0146997,,,NA,,Disease,Atherosclerosis,NA,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,miRNA,miR-1028,RNA-RNA,Inhibit,RNA pull-down assay,NA,NA,NA,ceRNA,NA,NA,,34780888
HELLPAR,LINC-HELLP,12q23.2,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg04004561,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
HOTAIR,HOXC-AS4;HOXC11-AS1;NCRNA00072,12q13.13,HSALNG0091318,"HSALNT0189446,HSALNT0189447,HSALNT0189448,HSALNT0289004,HSALNT0368392,HSALNT0368393,HSALNT0368394,HSALNT0368395,HSALNT0368396,HSALNT0368397,HSALNT0368398,HSALNT0368399,HSALNT0368400,HSALNT0368401,HSALNT0368402,HSALNT0368403,HSALNT0368404,HSALNT0368405",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,PCG,TSLP,Protein-DNA,Promote,NA,NA,NA,NA,Chip;Q-RCR;Wetern blotting assay,NA,Insensitivity to antigrowth signals;Migration;Invasion;Metastasis;Cancer proliferation,NA,Transcriptional regulation,NA,NA,"Thymic stromal lymphopoietin-induced hotair activation promotes endothelial cell proliferation and migration in atherosclerosis.Tslp activated hotair transcription through pi3k/akt-irf1 pathway and then regulates the ec proliferation and migration.Tslp-hotair axis also plays a protective role in low-density lipoprotein (ox-ldl)-induced ec injury.Taken together,tslp-hotair may be a potential therapy for ec dysfunction in atherosclerosis.",28615347
HOTAIR,HOXC-AS4;HOXC11-AS1;NCRNA00072,12q13.13,HSALNG0091318,"HSALNT0189446,HSALNT0189447,HSALNT0189448,HSALNT0289004,HSALNT0368392,HSALNT0368393,HSALNT0368394,HSALNT0368395,HSALNT0368396,HSALNT0368397,HSALNT0368398,HSALNT0368399,HSALNT0368400,HSALNT0368401,HSALNT0368402,HSALNT0368403,HSALNT0368404,HSALNT0368405",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-330-5p,RNA-RNA,NA,Rip;Q-RCR;Luciferase reporter assay,NA,Inflammatory response,NA,ceRNA,NA,NA,"Silence of long intergenic noncoding rna hotair ameliorates oxidative stress and inflammation response in ox-ldl-treated human macrophages by upregulating mir-330-5p.By carrying out bioinformatics analysis,mir-330-5p was predicted as a target of hotair and the correlation between them was validated in our current study.",30187491
HOTTIP,HOXA-AS6;RP1-170O19.3;HOXA13-AS1;NCRNA00213,7p15.2,HSALNG0056871,"HSALNT0120381,HSALNT0120382,HSALNT0120383,HSALNT0120385,HSALNT0120386,HSALNT0120387,HSALNT0120388,HSALNT0120390,HSALNT0120392,HSALNT0120397,HSALNT0339947,HSALNT0339948,HSALNT0339949,HSALNT0339950,HSALNT0339951,HSALNT0339952,HSALNT0339953,HSALNT0339954,HSALNT0339955,HSALNT0339956,HSALNT0339957",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG;PCG;TF,CCND1;PCNA;MYC,NA;NA;NA,promote;promote;promote,RNAi;Q-RCR,NA,Insensitivity to antigrowth signals;Migration;Invasion;Metastasis;Cancer proliferation,Wnt/β-catenin signaling pathway,NA,NA,NA,"Long noncoding rna hottip promotes endothelial cell proliferation and migration via activation of the wnt/beta-catenin pathway.Ectopic expression of hottip promoted endothelial cell proliferation and also increased the expression of proliferating makers cyclin d1 and pcnamoreover,elevated expression of hottip promoted endothelial cell migration.Downregulation expression of hottip suppressed endothelial cell proliferation and migration.Wedetermined that overexpression of hottip induced beta-catenin expression and enhanced the downstream protein c-myc expression in the endothelial cell.Ectopic expression of hottip increased endothelial cell proliferation and migration via activation of the wnt/beta-catenin pathway.",29058802
HOXA-AS2,HOXA3as,7p15.2,HSALNG0056854,"HSALNT0120328,HSALNT0120329,HSALNT0120330,HSALNT0120332,HSALNT0120334,HSALNT0120335,HSALNT0120337,HSALNT0120338,HSALNT0120340,HSALNT0120343,HSALNT0120344,HSALNT0120345,HSALNT0120347,HSALNT0120350,HSALNT0120351,HSALNT0339890,HSALNT0339891,HSALNT0339892,HSALNT0339893,HSALNT0339894,HSALNT0339895,HSALNT0339896,HSALNT0339897,HSALNT0339898,HSALNT0339899,HSALNT0339900,HSALNT0339901,HSALNT0339902,HSALNT0339903,HSALNT0339904,HSALNT0339905,HSALNT0339906,HSALNT0339907,HSALNT0339908,HSALNT0339909,HSALNT0339910,HSALNT0339911,HSALNT0339915",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg09591524;cg00899400;cg21134232;cg02439266;cg26297005;cg02627455;cg17800708;cg01027532;cg18430152;cg19817912;cg00431187;cg09798023;cg04778178;cg19999161;cg21556281;cg09469665;cg00318947;cg12305431;cg14216068;cg19048532;cg07153966;cg04351734,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
HOXA-AS3,HOXA6as,7p15.2,HSALNG0056858,"HSALNT0120349,HSALNT0120352,HSALNT0120353,HSALNT0120357,HSALNT0120359,HSALNT0289449,HSALNT0339916,HSALNT0339917,HSALNT0339918,HSALNT0339920,HSALNT0339921,HSALNT0339922",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg00903308;cg01414882;cg19816811;cg23590202;cg02919960,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
HOXA-AS3,HOXA6as,7p15.2,HSALNG0056858,"HSALNT0120349,HSALNT0120352,HSALNT0120353,HSALNT0120357,HSALNT0120359,HSALNT0289449,HSALNT0339916,HSALNT0339917,HSALNT0339918,HSALNT0339920,HSALNT0339921,HSALNT0339922",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg19183743,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,29436575
HOXA10-AS,HOXA-AS4,7p15.2,HSALNG0056863,"HSALNT0120363,HSALNT0120364,HSALNT0120365,HSALNT0120366,HSALNT0339923,HSALNT0339924,HSALNT0339925,HSALNT0339926,HSALNT0339927,HSALNT0339928,HSALNT0339929,HSALNT0339930",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg02886033;cg01819512,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
HOXA10-AS,HOXA-AS4,7p15.2,HSALNG0056863,"HSALNT0120363,HSALNT0120364,HSALNT0120365,HSALNT0120366,HSALNT0339923,HSALNT0339924,HSALNT0339925,HSALNT0339926,HSALNT0339927,HSALNT0339928,HSALNT0339929,HSALNT0339930",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg10224937;cg23854860;cg21310745,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,29436575
HOXB-AS3,,17q21.32,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg15255390,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
HOXC-AS1,,12q13.13,,,,NA,,Disease,atherosclerosis,Blood;Thp1,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,HOXC6,NA,NA,Microarray;QRT-PCR;Wetern blotting assay,NA,NA,NA,NA,NA,NA,Lentivirus-mediated overexpression of hoxc-as1 induced hoxc6 expression at mrna and protein levels in thp-1 macrophages.Induction of cholesterol accumulation by ox-ldl could be partly suppressed by overexpression of hoxc-as1.,27574949
HULC,NCRNA00078;LINC00078;HCCAT1,6p24.3,HSALNG0047929,"HSALNT0100946,HSALNT0100947,HSALNT0100948,HSALNT0100951,HSALNT0100958,HSALNT0100959,HSALNT0100960,HSALNT0100961,HSALNT0100962,HSALNT0100965,HSALNT0100966,HSALNT0100967,HSALNT0100968,HSALNT0100969,HSALNT0100970,HSALNT0100971,HSALNT0100972,HSALNT0100974,HSALNT0100975,HSALNT0100979,HSALNT0100980,HSALNT0100981,HSALNT0100982,HSALNT0100983,HSALNT0100985,HSALNT0100987,HSALNT0100988,HSALNT0100989,HSALNT0100997,HSALNT0100998,HSALNT0101007,HSALNT0101008,HSALNT0101009,HSALNT0101010,HSALNT0101011,HSALNT0101012,HSALNT0101013,HSALNT0101014,HSALNT0101015,HSALNT0101017,HSALNT0101020,HSALNT0101023,HSALNT0101028,HSALNT0101030,HSALNT0101031,HSALNT0101032,HSALNT0101033,HSALNT0101037,HSALNT0101038,HSALNT0101042,HSALNT0101043,HSALNT0101046,HSALNT0101047,HSALNT0101053,HSALNT0101055,HSALNT0101056,HSALNT0101057,HSALNT0101058,HSALNT0101059,HSALNT0101060,HSALNT0101061,HSALNT0101062,HSALNT0101063,HSALNT0101064,HSALNT0101065,HSALNT0101066,HSALNT0101067,HSALNT0101068,HSALNT0101070,HSALNT0101071,HSALNT0101072,HSALNT0101073,HSALNT0101074,HSALNT0101075,HSALNT0101076,HSALNT0101077,HSALNT0101078,HSALNT0101079,HSALNT0101080,HSALNT0101081,HSALNT0101094,HSALNT0101095,HSALNT0101097,HSALNT0101098,HSALNT0289007,HSALNT0332209,HSALNT0332210,HSALNT0332211,HSALNT0332212,HSALNT0332213,HSALNT0332214,HSALNT0332215,HSALNT0332216,HSALNT0332217,HSALNT0332218,HSALNT0332219,HSALNT0332220,HSALNT0332221,HSALNT0332222,HSALNT0332223,HSALNT0332224,HSALNT0332225,HSALNT0332226,HSALNT0332227,HSALNT0332228,HSALNT0332229,HSALNT0332230,HSALNT0332231,HSALNT0332232,HSALNT0332233,HSALNT0332234,HSALNT0332235,HSALNT0332236,HSALNT0332237,HSALNT0332238,HSALNT0332239,HSALNT0332240,HSALNT0332241,HSALNT0332242,HSALNT0332243,HSALNT0332244,HSALNT0332245,HSALNT0332252,HSALNT0332253,HSALNT0332254,HSALNT0332255,HSALNT0332256,HSALNT0332257,HSALNT0332258,HSALNT0332259,HSALNT0332260,HSALNT0332261,HSALNT0332262,HSALNT0332263,HSALNT0332264,HSALNT0332265,HSALNT0332266,HSALNT0332267,HSALNT0332268,HSALNT0332269,HSALNT0332270,HSALNT0332271,HSALNT0332272,HSALNT0332273,HSALNT0332274,HSALNT0332275,HSALNT0332276,HSALNT0332277,HSALNT0332278,HSALNT0332279,HSALNT0332280,HSALNT0332281,HSALNT0332282,HSALNT0332283,HSALNT0332284,HSALNT0332285,HSALNT0332286,HSALNT0332287,HSALNT0332288,HSALNT0332289,HSALNT0332290,HSALNT0332291,HSALNT0332292,HSALNT0332293,HSALNT0332294,HSALNT0332295,HSALNT0332296,HSALNT0332297,HSALNT0332298,HSALNT0332299,HSALNT0332300,HSALNT0332301,HSALNT0332302,HSALNT0332303,HSALNT0332304,HSALNT0332305,HSALNT0332306,HSALNT0332307,HSALNT0332308,HSALNT0332309,HSALNT0332310,HSALNT0332311,HSALNT0332312,HSALNT0332313,HSALNT0332314,HSALNT0332315,HSALNT0332316,HSALNT0332317,HSALNT0332318,HSALNT0332319,HSALNT0332320,HSALNT0332321,HSALNT0332322,HSALNT0332323,HSALNT0332324,HSALNT0332325,HSALNT0332326,HSALNT0332327,HSALNT0332328,HSALNT0332329,HSALNT0332330,HSALNT0332331,HSALNT0332332,HSALNT0332333,HSALNT0332334,HSALNT0332335,HSALNT0332336,HSALNT0332337,HSALNT0332338,HSALNT0332339,HSALNT0332340,HSALNT0332341,HSALNT0332342,HSALNT0332343,HSALNT0332344,HSALNT0332345,HSALNT0332346,HSALNT0332347,HSALNT0332348,HSALNT0332349,HSALNT0332350,HSALNT0332351,HSALNT0332352,HSALNT0332353,HSALNT0332354,HSALNT0332355,HSALNT0332356,HSALNT0332357,HSALNT0332358,HSALNT0332359,HSALNT0332360,HSALNT0332361,HSALNT0332362,HSALNT0332363,HSALNT0332364,HSALNT0332365,HSALNT0332366,HSALNT0332367,HSALNT0332368,HSALNT0332369,HSALNT0332370,HSALNT0332371,HSALNT0332372,HSALNT0332373,HSALNT0332374,HSALNT0332375,HSALNT0332376,HSALNT0332377,HSALNT0332378,HSALNT0332379,HSALNT0332380,HSALNT0332381,HSALNT0332382,HSALNT0332383,HSALNT0332384,HSALNT0332385,HSALNT0332386,HSALNT0332387,HSALNT0332388,HSALNT0332390,HSALNT0332391,HSALNT0332392,HSALNT0332393,HSALNT0332394,HSALNT0332395,HSALNT0332396,HSALNT0332397,HSALNT0332398,HSALNT0332399,HSALNT0332400,HSALNT0332401,HSALNT0332402,HSALNT0332403,HSALNT0332404,HSALNT0332405,HSALNT0332406,HSALNT0332407,HSALNT0332408,HSALNT0332409,HSALNT0332410,HSALNT0332414",,NA,,Disease,atherosclerosis,Liver;Hepg2;Hepg2.2.15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,E2F1,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hulc activated the promoter of sphk1 in hepatoma cells through the transcription factor e2f1.Chromatin immunoprecipitation (chip) and electrophoretic mobility shift assay (emsa) further showed that e2f1 was capable of binding to the e2f1 element in the sphk1 promoter.,26540633
HULC,NCRNA00078;LINC00078;HCCAT1,6p24.3,HSALNG0047929,"HSALNT0100946,HSALNT0100947,HSALNT0100948,HSALNT0100951,HSALNT0100958,HSALNT0100959,HSALNT0100960,HSALNT0100961,HSALNT0100962,HSALNT0100965,HSALNT0100966,HSALNT0100967,HSALNT0100968,HSALNT0100969,HSALNT0100970,HSALNT0100971,HSALNT0100972,HSALNT0100974,HSALNT0100975,HSALNT0100979,HSALNT0100980,HSALNT0100981,HSALNT0100982,HSALNT0100983,HSALNT0100985,HSALNT0100987,HSALNT0100988,HSALNT0100989,HSALNT0100997,HSALNT0100998,HSALNT0101007,HSALNT0101008,HSALNT0101009,HSALNT0101010,HSALNT0101011,HSALNT0101012,HSALNT0101013,HSALNT0101014,HSALNT0101015,HSALNT0101017,HSALNT0101020,HSALNT0101023,HSALNT0101028,HSALNT0101030,HSALNT0101031,HSALNT0101032,HSALNT0101033,HSALNT0101037,HSALNT0101038,HSALNT0101042,HSALNT0101043,HSALNT0101046,HSALNT0101047,HSALNT0101053,HSALNT0101055,HSALNT0101056,HSALNT0101057,HSALNT0101058,HSALNT0101059,HSALNT0101060,HSALNT0101061,HSALNT0101062,HSALNT0101063,HSALNT0101064,HSALNT0101065,HSALNT0101066,HSALNT0101067,HSALNT0101068,HSALNT0101070,HSALNT0101071,HSALNT0101072,HSALNT0101073,HSALNT0101074,HSALNT0101075,HSALNT0101076,HSALNT0101077,HSALNT0101078,HSALNT0101079,HSALNT0101080,HSALNT0101081,HSALNT0101094,HSALNT0101095,HSALNT0101097,HSALNT0101098,HSALNT0289007,HSALNT0332209,HSALNT0332210,HSALNT0332211,HSALNT0332212,HSALNT0332213,HSALNT0332214,HSALNT0332215,HSALNT0332216,HSALNT0332217,HSALNT0332218,HSALNT0332219,HSALNT0332220,HSALNT0332221,HSALNT0332222,HSALNT0332223,HSALNT0332224,HSALNT0332225,HSALNT0332226,HSALNT0332227,HSALNT0332228,HSALNT0332229,HSALNT0332230,HSALNT0332231,HSALNT0332232,HSALNT0332233,HSALNT0332234,HSALNT0332235,HSALNT0332236,HSALNT0332237,HSALNT0332238,HSALNT0332239,HSALNT0332240,HSALNT0332241,HSALNT0332242,HSALNT0332243,HSALNT0332244,HSALNT0332245,HSALNT0332252,HSALNT0332253,HSALNT0332254,HSALNT0332255,HSALNT0332256,HSALNT0332257,HSALNT0332258,HSALNT0332259,HSALNT0332260,HSALNT0332261,HSALNT0332262,HSALNT0332263,HSALNT0332264,HSALNT0332265,HSALNT0332266,HSALNT0332267,HSALNT0332268,HSALNT0332269,HSALNT0332270,HSALNT0332271,HSALNT0332272,HSALNT0332273,HSALNT0332274,HSALNT0332275,HSALNT0332276,HSALNT0332277,HSALNT0332278,HSALNT0332279,HSALNT0332280,HSALNT0332281,HSALNT0332282,HSALNT0332283,HSALNT0332284,HSALNT0332285,HSALNT0332286,HSALNT0332287,HSALNT0332288,HSALNT0332289,HSALNT0332290,HSALNT0332291,HSALNT0332292,HSALNT0332293,HSALNT0332294,HSALNT0332295,HSALNT0332296,HSALNT0332297,HSALNT0332298,HSALNT0332299,HSALNT0332300,HSALNT0332301,HSALNT0332302,HSALNT0332303,HSALNT0332304,HSALNT0332305,HSALNT0332306,HSALNT0332307,HSALNT0332308,HSALNT0332309,HSALNT0332310,HSALNT0332311,HSALNT0332312,HSALNT0332313,HSALNT0332314,HSALNT0332315,HSALNT0332316,HSALNT0332317,HSALNT0332318,HSALNT0332319,HSALNT0332320,HSALNT0332321,HSALNT0332322,HSALNT0332323,HSALNT0332324,HSALNT0332325,HSALNT0332326,HSALNT0332327,HSALNT0332328,HSALNT0332329,HSALNT0332330,HSALNT0332331,HSALNT0332332,HSALNT0332333,HSALNT0332334,HSALNT0332335,HSALNT0332336,HSALNT0332337,HSALNT0332338,HSALNT0332339,HSALNT0332340,HSALNT0332341,HSALNT0332342,HSALNT0332343,HSALNT0332344,HSALNT0332345,HSALNT0332346,HSALNT0332347,HSALNT0332348,HSALNT0332349,HSALNT0332350,HSALNT0332351,HSALNT0332352,HSALNT0332353,HSALNT0332354,HSALNT0332355,HSALNT0332356,HSALNT0332357,HSALNT0332358,HSALNT0332359,HSALNT0332360,HSALNT0332361,HSALNT0332362,HSALNT0332363,HSALNT0332364,HSALNT0332365,HSALNT0332366,HSALNT0332367,HSALNT0332368,HSALNT0332369,HSALNT0332370,HSALNT0332371,HSALNT0332372,HSALNT0332373,HSALNT0332374,HSALNT0332375,HSALNT0332376,HSALNT0332377,HSALNT0332378,HSALNT0332379,HSALNT0332380,HSALNT0332381,HSALNT0332382,HSALNT0332383,HSALNT0332384,HSALNT0332385,HSALNT0332386,HSALNT0332387,HSALNT0332388,HSALNT0332390,HSALNT0332391,HSALNT0332392,HSALNT0332393,HSALNT0332394,HSALNT0332395,HSALNT0332396,HSALNT0332397,HSALNT0332398,HSALNT0332399,HSALNT0332400,HSALNT0332401,HSALNT0332402,HSALNT0332403,HSALNT0332404,HSALNT0332405,HSALNT0332406,HSALNT0332407,HSALNT0332408,HSALNT0332409,HSALNT0332410,HSALNT0332414",,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rip;Chip;Luciferase reporter gene assay;Q-RCR,NA,NA,NA,NA,NA,NA,Hulc-mir-9 pathway may be a potential target for treating atherosclerosis.,26981838
KCNQ1OT1,,,,,,NA,,Disease,Atherosclerosis,293 T;THP-1,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-137,RNA-RNA,Inhibit,NA,oxidative stress,Inflammatory response,NA,ceRNA,NA,oxidized low-density lipoprotein treated,,35598525
LINC00305,MGC39571;HsT1235;C18orf20;NCRNA00305,18q22.1,HSALNG0122085,"HSALNT0252381,HSALNT0252382,HSALNT0252383,HSALNT0252384,HSALNT0252385,HSALNT0252386,HSALNT0252387,HSALNT0252391,HSALNT0252392,HSALNT0252394,HSALNT0394846,HSALNT0394847,HSALNT0394848,HSALNT0394849,HSALNT0394850,HSALNT0394851,HSALNT0394852,HSALNT0394853,HSALNT0394854,HSALNT0394855,HSALNT0394856,HSALNT0394857,HSALNT0394858,HSALNT0394859,HSALNT0394860,HSALNT0394861,HSALNT0394862,HSALNT0394865",,NA,,Disease,atherosclerosis,Blood;Thp1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,LIMR,NA,NA,Rnanafish;Rna pullnadown assay;Immunofluorescence assays;Rna immunoprecipitation (rip) assay,NA,NA,NA,NA,NA,NA,"Mechanistically,linc00305 interacted with lipocalin-1 interacting membrane receptor (limr),enhanced the interaction of limr and aryl-hydrocarbon receptor repressor (ahrr),and promoted protein expression as well as nuclear localization of ahrr.Moreover,linc00305 activated nf-κb  exclusively in the presence of limr and ahrr.In light of these findings,wepropose that linc00305 promotes monocyte inflammation by facilitating limr and ahrr cooperation and the ahrr activation,which eventually activates nf-κb ,thereby inducing hasmc phenotype switching.",28393844
LINC00472,dJ288M22.3;FLJ13189;P53RRA;C6orf155,6q13,HSALNG0051162,"HSALNT0108223,HSALNT0108225,HSALNT0108226,HSALNT0108227,HSALNT0108228,HSALNT0108229,HSALNT0108231,HSALNT0108232,HSALNT0108233,HSALNT0108234,HSALNT0108235,HSALNT0108236,HSALNT0108237,HSALNT0108238,HSALNT0108239,HSALNT0108240,HSALNT0108241,HSALNT0108242,HSALNT0108243,HSALNT0108244,HSALNT0108245,HSALNT0108246,HSALNT0108247,HSALNT0108248,HSALNT0108249,HSALNT0108250,HSALNT0108251,HSALNT0108252,HSALNT0108253,HSALNT0108256,HSALNT0108257,HSALNT0108258,HSALNT0108259,HSALNT0108260,HSALNT0108261,HSALNT0108262,HSALNT0108263,HSALNT0108271,HSALNT0108276,HSALNT0108278,HSALNT0108279,HSALNT0108287,HSALNT0108288,HSALNT0108291,HSALNT0108300,HSALNT0108301,HSALNT0108302,HSALNT0289041,HSALNT0335021,HSALNT0335022,HSALNT0335023,HSALNT0335024,HSALNT0335025,HSALNT0335027,HSALNT0335029,HSALNT0335030,HSALNT0335031,HSALNT0335032,HSALNT0335033,HSALNT0335034,HSALNT0335035,HSALNT0335036,HSALNT0335037,HSALNT0335038,HSALNT0335039,HSALNT0335040,HSALNT0335041,HSALNT0335042,HSALNT0335043,HSALNT0335044,HSALNT0335045,HSALNT0335046,HSALNT0335047,HSALNT0335048,HSALNT0335049,HSALNT0335050,HSALNT0335051,HSALNT0335052,HSALNT0335053,HSALNT0335054",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg00929496,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC00852,NAG73;GHRL-AS2;C3orf42;GHRLOS2,3p25.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg16204414,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC00923,,15q26.2,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg10328844,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC01006,MY040;C7orf13,7q36.3,HSALNG0062663,"HSALNT0131426,HSALNT0131427,HSALNT0131428,HSALNT0131429,HSALNT0131430,HSALNT0131431,HSALNT0131432,HSALNT0131433,HSALNT0131436,HSALNT0131437,HSALNT0131446,HSALNT0131447,HSALNT0131448,HSALNT0131449,HSALNT0131450,HSALNT0131453,HSALNT0344426,HSALNT0344427,HSALNT0344428,HSALNT0344429,HSALNT0344430,HSALNT0344431,HSALNT0344432,HSALNT0344433,HSALNT0344434,HSALNT0344435,HSALNT0344436,HSALNT0344437,HSALNT0344438,HSALNT0344439,HSALNT0344440,HSALNT0344441,HSALNT0344442,HSALNT0344443,HSALNT0344444,HSALNT0344445,HSALNT0344451,HSALNT0344452,HSALNT0344453,HSALNT0344454",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg23786812,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC01705,RP11-400N13.3,1q41,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg09894814,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC02590,AC016735.2,2p21,HSALNG0014513,"HSALNT0030809,HSALNT0302078",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg21241410,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28698603
LINC02886,RP11-697M17.1,8q21.13,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg12992268,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
LINC02904,FLJ37131;C8orf31,8q24.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg25471715,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
MALAT1,PRO1073;MALAT-1;NCRNA00047;HCN;NEAT2;LINC00047;mascRNA,11q13.1,HSALNG0084905,"HSALNT0176789,HSALNT0176790,HSALNT0176796,HSALNT0176798,HSALNT0176802,HSALNT0176803,HSALNT0176804,HSALNT0176807,HSALNT0176808,HSALNT0176810,HSALNT0176813,HSALNT0176815,HSALNT0176817,HSALNT0176818,HSALNT0176819,HSALNT0176821,HSALNT0176823,HSALNT0176825,HSALNT0176826,HSALNT0176827,HSALNT0176830,HSALNT0176832,HSALNT0176833,HSALNT0176835,HSALNT0176837,HSALNT0176838,HSALNT0289363,HSALNT0363299,HSALNT0363300,HSALNT0363301,HSALNT0363302,HSALNT0363303,HSALNT0363304,HSALNT0363305,HSALNT0363306,HSALNT0363307,HSALNT0363308,HSALNT0363309,HSALNT0363310,HSALNT0363311,HSALNT0363312,HSALNT0363313,HSALNT0363315,HSALNT0363316,HSALNT0363317,HSALNT0363318,HSALNT0363319,HSALNT0363320,HSALNT0363321,HSALNT0363322,HSALNT0363323,HSALNT0363324,HSALNT0363325",Y,NA,Mammal,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,SOCS1,NA,Promote,QRT-PCR;Luciferase reporter assay,NA,Evading apoptosis;Inflammatory response;Apoptosis,NA,ceRNA,NA,NA,"The suppression of ox-ldl-induced inflammatory cytokine release and apoptosis of hcaecs by long non-coding rna-malat1 via regulating microrna-155/socs1 pathway.We found that malat1 could suppress the inflammatory cytokine release and cell apoptosis via sponging mir-155 to increase socs1 level,which in turn restrained jak-stat pathway.Mir-155 regulatedthe production of pro-inflammatory cytokines and theapoptosis of hcaecs via directly targeting socs1.",30314869
MEG3,GTL2;NCRNA00023;LINC00023;onco-lncRNA-83,14q32.2,,,Y,Mouse,Mammal,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA;PCG,miR-223;NLRP3,RNA-RNA;NA,NA;promote,Q-RCR;Luciferase reporter assay,NA,Evading apoptosis,Wnt/β-catenin signaling pathway,ceRNA,NA,NA,"Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding rna meg3/mir-223/nlrp3 axis.We found that lncRNA meg3 enhanced pyroptosis in haecs.Moreover,meg3 acted as an endogenous sponge by sequence complementarity to suppress the function of mir-223 and to increase nlrp3 expression and enhance endothelial cell pyroptosis.",29024030
MIAT,FLJ25967;Rncr2;gomafu;NCRNA00066;LINC00066;lncRNA-MIAT;C22orf35,22q12.1,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,TF,STAT3,NA,Promote,Rip;QRT-PCR;Wetern blotting assay;Luciferase reporter assay,NA,Evading apoptosis;Cancer proliferation;Apoptosis;Insensitivity to antigrowth signals,Chemokine signaling pathway;Adipocytokine signaling pathway;Jak-stat signaling pathway;Hif-1 signaling pathway,ceRNA,NA,NA,"Miat promotes proliferation and hinders apoptosis by modulating mir-181b/stat3 axis in ox-ldl-induced atherosclerosis cell models.Moreover,miat enhanced stat3 expression through sequestering mir-181b as a molecular sponge.Furthermore,mir-181b hindered cell growth,induced cell cycle arrest and promoted apoptosis by directly targeting stat3.",29136944
MIR100HG,AGD1;lncRNA-N2;linc-NeD125,11q24.1,HSALNG0087764,"HSALNT0182356,HSALNT0182357,HSALNT0182358,HSALNT0182359,HSALNT0182360,HSALNT0182361,HSALNT0182362,HSALNT0182363,HSALNT0182370,HSALNT0182371,HSALNT0182372,HSALNT0182373,HSALNT0182374,HSALNT0182375,HSALNT0182377,HSALNT0182378,HSALNT0182379,HSALNT0182381,HSALNT0182383,HSALNT0182385,HSALNT0182387,HSALNT0182388,HSALNT0182389,HSALNT0182391,HSALNT0182393,HSALNT0182395,HSALNT0182399,HSALNT0182402,HSALNT0182403,HSALNT0182405,HSALNT0182407,HSALNT0182409,HSALNT0182414,HSALNT0182415,HSALNT0182416,HSALNT0182418,HSALNT0182421,HSALNT0182422,HSALNT0182426,HSALNT0182427,HSALNT0182428,HSALNT0182429,HSALNT0182431,HSALNT0182432,HSALNT0182434,HSALNT0182437,HSALNT0182438,HSALNT0182441,HSALNT0182442,HSALNT0182447,HSALNT0182449,HSALNT0182451,HSALNT0182452,HSALNT0182455,HSALNT0182457,HSALNT0182459,HSALNT0182461,HSALNT0182462,HSALNT0182464,HSALNT0182465,HSALNT0182467,HSALNT0182469,HSALNT0182482,HSALNT0182484,HSALNT0182499,HSALNT0182501,HSALNT0182503,HSALNT0182505,HSALNT0182506,HSALNT0182508,HSALNT0182510,HSALNT0182512,HSALNT0182514,HSALNT0182517,HSALNT0182518,HSALNT0182523,HSALNT0182531,HSALNT0182532,HSALNT0182534,HSALNT0182548,HSALNT0182549,HSALNT0289173,HSALNT0365357,HSALNT0365358,HSALNT0365359,HSALNT0365360,HSALNT0365361,HSALNT0365362,HSALNT0365363,HSALNT0365364,HSALNT0365365,HSALNT0365366,HSALNT0365367,HSALNT0365368,HSALNT0365369,HSALNT0365370,HSALNT0365371,HSALNT0365372,HSALNT0365373,HSALNT0365374,HSALNT0365375,HSALNT0365376,HSALNT0365377,HSALNT0365378,HSALNT0365379,HSALNT0365380,HSALNT0365381,HSALNT0365382,HSALNT0365383,HSALNT0365384,HSALNT0365385,HSALNT0365386,HSALNT0365387,HSALNT0365388,HSALNT0365389,HSALNT0365390,HSALNT0365391,HSALNT0365392,HSALNT0365393,HSALNT0365394,HSALNT0365395,HSALNT0365396,HSALNT0365397,HSALNT0365398,HSALNT0365399,HSALNT0365400,HSALNT0365401,HSALNT0365402,HSALNT0365403,HSALNT0365404,HSALNT0365405,HSALNT0365406,HSALNT0365407,HSALNT0365408,HSALNT0365409,HSALNT0365410,HSALNT0365411,HSALNT0365412,HSALNT0365413,HSALNT0365414,HSALNT0365415,HSALNT0365416,HSALNT0365417,HSALNT0365418,HSALNT0365419,HSALNT0365420,HSALNT0365421,HSALNT0365422,HSALNT0365423,HSALNT0365424,HSALNT0365425,HSALNT0365426,HSALNT0365427,HSALNT0365428,HSALNT0365429,HSALNT0365430,HSALNT0365431,HSALNT0365432,HSALNT0365433,HSALNT0365434,HSALNT0365435,HSALNT0365436,HSALNT0365437,HSALNT0365438,HSALNT0365439,HSALNT0365440,HSALNT0365441,HSALNT0365442,HSALNT0365443,HSALNT0365444,HSALNT0365445,HSALNT0365446,HSALNT0365447,HSALNT0365448,HSALNT0365449,HSALNT0365450,HSALNT0365451,HSALNT0365452,HSALNT0365453,HSALNT0365454,HSALNT0365455,HSALNT0365456,HSALNT0365457,HSALNT0365458",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg23602690;cg21170682;cg27212940;cg05678526;cg08181212;cg13123165,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
MIR193BHG,lincNORS,16p13.12,HSALNG0109730,"HSALNT0227964,HSALNT0227965,HSALNT0227968,HSALNT0227969,HSALNT0227970,HSALNT0227975,HSALNT0227976,HSALNT0227977,HSALNT0227979,HSALNT0227981,HSALNT0227983,HSALNT0227984,HSALNT0227985,HSALNT0227986,HSALNT0227987,HSALNT0227988,HSALNT0227989,HSALNT0227990,HSALNT0227991,HSALNT0227992,HSALNT0384665,HSALNT0384666,HSALNT0384667,HSALNT0384668,HSALNT0384669,HSALNT0384670,HSALNT0384671,HSALNT0384672,HSALNT0384673,HSALNT0384674,HSALNT0384675,HSALNT0384676,HSALNT0384677,HSALNT0384678,HSALNT0384679,HSALNT0384680,HSALNT0384681,HSALNT0384682,HSALNT0384683,HSALNT0384684,HSALNT0384685,HSALNT0384686,HSALNT0384687,HSALNT0384688,HSALNT0384689,HSALNT0384690,HSALNT0384691,HSALNT0384692",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg02533339,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
MIRLET7BHG,linc-Ppara,22q13.31,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg19764731,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
NCK1-DT,SLC35G2-AS1;NCK1-AS1,3q22.3,HSALNG0029189,,,NA,,Disease,Atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-1197,RNA-RNA,Inhibit,NA,NA,Apoptosis,NA,ceRNA,NA,NA,,34986861
NEAT1,TncRNA;MENepsilon/beta;LINC00084;VINC;NCRNA00084,11q13.1,HSALNG0084892,"HSALNT0176751,HSALNT0176753,HSALNT0176757,HSALNT0176758,HSALNT0176759,HSALNT0176762,HSALNT0176765,HSALNT0289192,HSALNT0363258,HSALNT0363259,HSALNT0363260,HSALNT0363261,HSALNT0363262,HSALNT0363263,HSALNT0363264,HSALNT0363265,HSALNT0363266,HSALNT0363267,HSALNT0363268,HSALNT0363269,HSALNT0363270,HSALNT0363271,HSALNT0363272,HSALNT0363273,HSALNT0363274,HSALNT0363275,HSALNT0363276,HSALNT0363277,HSALNT0363278,HSALNT0363279,HSALNT0363280,HSALNT0363281,HSALNT0363282,HSALNT0363283,HSALNT0363284,HSALNT0363285,HSALNT0363286,HSALNT0363287,HSALNT0363289",Y,NA,Placental mammal,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-342-3p,NA,Inhibit,Rip;QRT-PCR;Luciferase reporter assay,NA,Inflammatory response,NA,Transcriptional regulation,NA,NA,"Blockade of neat1 represses inflammation response and lipid uptake via modulating mir-342-3p in human macrophages thp-1 cells.Mir-342-3p was predicted as a downstream target of neat1 and the correlation between them was confirmed in our study.Moreover,overexpression of mir-342-3p could also greatly suppress inflammation response and lipid uptake in thp-1 cells.Weobserved that neat1 was significantly increased in thp-1 cells.",30259979
NGF-AS1,RP4-663N10.1,1p13.2,HSALNG0006265,"HSALNT0013095,HSALNT0013096,HSALNT0013097,HSALNT0013098,HSALNT0013099,HSALNT0013100,HSALNT0013101,HSALNT0013103,HSALNT0013104,HSALNT0013105,HSALNT0013111,HSALNT0013112,HSALNT0013113,HSALNT0294811,HSALNT0294812,HSALNT0294814,HSALNT0294815,HSALNT0294816,HSALNT0294817,HSALNT0294818,HSALNT0294819",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg07037778,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
PART1,DKFZP586D0823;NCRNA00206,5q12.1,HSALNG0042101,"HSALNT0088414,HSALNT0088418,HSALNT0088420,HSALNT0088421,HSALNT0088425,HSALNT0088426,HSALNT0088427,HSALNT0088428,HSALNT0088429,HSALNT0088430,HSALNT0326808,HSALNT0326809,HSALNT0326810,HSALNT0326811,HSALNT0326812,HSALNT0326813,HSALNT0326814,HSALNT0326815,HSALNT0326816,HSALNT0326817,HSALNT0326818,HSALNT0326819,HSALNT0326820,HSALNT0326821,HSALNT0326822,HSALNT0326823,HSALNT0326824,HSALNT0326825,HSALNT0326830,HSALNT0326831,HSALNT0326832",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg05141014,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
PCAT1,PCAT-1;PCA1;PiHL,8q24.21,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg25883066,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
PCAT7,PCAN-R2,9q22.32,HSALNG0072923,"HSALNT0152401,HSALNT0152402,HSALNT0152403,HSALNT0152404,HSALNT0152405,HSALNT0152406,HSALNT0152407,HSALNT0152408,HSALNT0152409,HSALNT0152410,HSALNT0152411,HSALNT0152412,HSALNT0152413,HSALNT0152414,HSALNT0152415,HSALNT0152416,HSALNT0152418,HSALNT0152419,HSALNT0152421,HSALNT0152422,HSALNT0152423,HSALNT0152424,HSALNT0152425,HSALNT0152426,HSALNT0152427,HSALNT0152428,HSALNT0152429,HSALNT0152431,HSALNT0289210,HSALNT0353775,HSALNT0353776,HSALNT0353777,HSALNT0353778,HSALNT0353779,HSALNT0353780,HSALNT0353781,HSALNT0353782,HSALNT0353783,HSALNT0353784,HSALNT0353785,HSALNT0353786,HSALNT0353787",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg01197831,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
SCIRT,,6p21.1,ENSG00000237686,,,NA,,Disease,atherosclerosis,Artery,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,miRNA,miR-146a,RNA-RNA,Inhibit,NA,NA,Cancer proliferation,NA,ceRNA,NA,NA,,34742341
SMILR,,8q24.13,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,HAS2,NA,Promote,QRT-PCR;RNAi;Sequencing,NA,Cancer proliferation;Insensitivity to antigrowth signals,NA,NA,NA,NA,"Smooth muscle enriched long noncoding rna (smilr) regulates cell proliferation.Knockdown of smilr markedly reduced cell proliferation.We focused on a novel lncRNA (ensembl: rp11-94a24.1),which wetermed smooth muscle-induced lncRNA enhances replication (smilr).Following stimulation,smilr expression was increased in both the nucleus and cytoplasm,and was detected in conditioned media.Furthermore,knockdown of smilr markedly reduced cell proliferation.Mechanistically,wenoted that expression of genes proximal to smilr was also altered by interleukin-1alpha/platelet-derived growth factor treatment,and has2 expression was reduced by smilr knockdown.",27052414
SNHG12,,1p35.3,ENSG00000197989,,,NA,,Disease,Atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-1301-3p,RNA-RNA,Inhibit,NA,NA,Cell growth;Migration;Apoptosis,NA,ceRNA,NA,NA,,34847450
SNHG29,MGC40157;C17orf45;NCRNA00188;C17orf76-AS1;FAM211A-AS1;LRRC75A-AS1,17p11.2,HSALNG0114857,"HSALNT0237737,HSALNT0237775,HSALNT0237776,HSALNT0237777,HSALNT0237778,HSALNT0237779,HSALNT0237780,HSALNT0237781,HSALNT0237782,HSALNT0237783,HSALNT0237784,HSALNT0237785,HSALNT0237786,HSALNT0237787,HSALNT0237788,HSALNT0237789,HSALNT0237790,HSALNT0237791,HSALNT0237792,HSALNT0237793,HSALNT0237794,HSALNT0237795,HSALNT0237796,HSALNT0237797,HSALNT0237798,HSALNT0237799,HSALNT0237800,HSALNT0237801,HSALNT0237802,HSALNT0237803,HSALNT0237804,HSALNT0237805,HSALNT0237806,HSALNT0237807,HSALNT0237808,HSALNT0237811,HSALNT0237812,HSALNT0237818,HSALNT0237819,HSALNT0237820,HSALNT0237821,HSALNT0237822,HSALNT0237823,HSALNT0237824,HSALNT0237825,HSALNT0237826,HSALNT0237827,HSALNT0237829,HSALNT0237830,HSALNT0237831,HSALNT0237832,HSALNT0237833,HSALNT0237835,HSALNT0237836,HSALNT0237839,HSALNT0237845,HSALNT0237846,HSALNT0237847,HSALNT0237848,HSALNT0237852,HSALNT0237855,HSALNT0237856,HSALNT0237857,HSALNT0237862,HSALNT0289155,HSALNT0388709,HSALNT0388710,HSALNT0388711,HSALNT0388712,HSALNT0388713,HSALNT0388714,HSALNT0388715,HSALNT0388716,HSALNT0388717,HSALNT0388718,HSALNT0388719,HSALNT0388720,HSALNT0388721,HSALNT0388722,HSALNT0388723,HSALNT0388724,HSALNT0388725,HSALNT0388726,HSALNT0388727,HSALNT0388728,HSALNT0388729,HSALNT0388730,HSALNT0388731,HSALNT0388732,HSALNT0388733,HSALNT0388734,HSALNT0388735,HSALNT0388736,HSALNT0388737,HSALNT0388738,HSALNT0388739,HSALNT0388740,HSALNT0388741,HSALNT0388742,HSALNT0388743,HSALNT0388744,HSALNT0388745,HSALNT0388746,HSALNT0388747,HSALNT0388748,HSALNT0388749,HSALNT0388750,HSALNT0388751,HSALNT0388752,HSALNT0388753,HSALNT0388754,HSALNT0388755,HSALNT0388756,HSALNT0388757,HSALNT0388758,HSALNT0388759,HSALNT0388760,HSALNT0388761,HSALNT0388762,HSALNT0388763,HSALNT0388764,HSALNT0388765,HSALNT0388766,HSALNT0388767,HSALNT0388768,HSALNT0388769,HSALNT0388770,HSALNT0388771,HSALNT0388772,HSALNT0388773,HSALNT0388774,HSALNT0388775,HSALNT0388776,HSALNT0388777,HSALNT0388778,HSALNT0388779,HSALNT0388780,HSALNT0388781,HSALNT0388782,HSALNT0388783",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg27615938,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28698603
SNHG32,D6S57;G8;C6orf48,6p21.33,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg01657995,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28698603
SNHG8,LINC00060;NCRNA00060,4q26,HSALNG0036656,,,NA,,Disease,Atherosclerosis,Artery tissue,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-224-3p,RNA-RNA,Inhibit,NA,NA,Cancer proliferation;Migration,Nf-κb signaling pathway,ceRNA,NA,NA,,34558393
SOX9-AS1,FLJ37644,17q24.3,,,,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg13544294,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
SPAG5-AS1,,17q11.2,HSALNG0115483,"HSALNT0238980,HSALNT0238981,HSALNT0238984,HSALNT0238985,HSALNT0238986,HSALNT0238987,HSALNT0238988,HSALNT0238989,HSALNT0238990,HSALNT0238992,HSALNT0238995,HSALNT0238997,HSALNT0238998,HSALNT0389192,HSALNT0389193,HSALNT0389194,HSALNT0389195,HSALNT0389196,HSALNT0389197,HSALNT0389198,HSALNT0389199,HSALNT0389200,HSALNT0389201,HSALNT0389202,HSALNT0389203,HSALNT0389204,HSALNT0389205,HSALNT0389206,HSALNT0389207",,NA,,Disease,atherosclerosis,NA,NA,NA,DNA methylation,cg09906647,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,25091541
TP53COR1,linc-p21;lincRNA-p21;Trp53cor1,6p21.2,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rip;QRT-PCR;Chip-seq,NA,NA,NA,NA,NA,NA,"The expression of lincrna-p21 was dramatically downregulated in atherosclerotic plaques of apoe(-/-) mice,an animal model for atherosclerosis.Lincrna-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro.",25156994
TP53COR1,linc-p21;lincRNA-p21;Trp53cor1,6p21.2,,,,NA,,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,OLR1,NA,Promote,RNAi;Q-RCR,NA,Evading apoptosis,NA,NA,NA,NA,Long intergenic noncoding rna p21 mediates oxidized ldl-induced apoptosis and expression of lox-1 in human coronary artery endothelial cells.Lentiviral overexpression of lincrna-p21 markedly increased oxldl-induced apoptosis and the expression of lox-1 in hcaecs.,28983628
TUG1,FLJ20618;NCRNA00080;LINC00080,22q12.2,HSALNG0134930,"HSALNT0276950,HSALNT0276953,HSALNT0276954,HSALNT0289417,HSALNT0405694,HSALNT0405695,HSALNT0405696,HSALNT0405697,HSALNT0405698,HSALNT0405699,HSALNT0405700,HSALNT0405701,HSALNT0405702,HSALNT0405703,HSALNT0405704,HSALNT0405705,HSALNT0405706,HSALNT0405707,HSALNT0405708,HSALNT0405709,HSALNT0405710,HSALNT0405711,HSALNT0405712,HSALNT0405713,HSALNT0405714,HSALNT0405715,HSALNT0405716,HSALNT0405717,HSALNT0405718",TRUE,N/A,Human;Mouse;Rat;Cow;Dog,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rip;Wetern blotting assay;Luciferase reporter gene assay;Q-RCR,NA,NA,NA,NA,NA,NA,Tanshinol suppresses endothelial cells apoptosis in mice with atherosclerosis via lncRNA tug1 up-regulating the expression of mir-26a.,27508018
UCA1,LINC00178;CUDR;UCAT1;onco-lncRNA-36,19p13.12,HSALNG0124349,"HSALNT0256280,HSALNT0256281,HSALNT0256282,HSALNT0256351,HSALNT0256352,HSALNT0256353,HSALNT0256354,HSALNT0256355,HSALNT0256357,HSALNT0256359,HSALNT0256365,HSALNT0256366,HSALNT0256488,HSALNT0256490,HSALNT0256492,HSALNT0256494,HSALNT0396290,HSALNT0396291,HSALNT0396292,HSALNT0396293,HSALNT0396294,HSALNT0396295,HSALNT0396296,HSALNT0396297,HSALNT0396298,HSALNT0396299,HSALNT0396300,HSALNT0396301,HSALNT0396302,HSALNT0396303,HSALNT0396304,HSALNT0396305,HSALNT0396306,HSALNT0396307,HSALNT0396308,HSALNT0396309,HSALNT0396310,HSALNT0396311,HSALNT0396312,HSALNT0396313,HSALNT0396314,HSALNT0396315,HSALNT0396316,HSALNT0396317,HSALNT0396318,HSALNT0396319,HSALNT0396320,HSALNT0396321,HSALNT0396322,HSALNT0396323,HSALNT0396324,HSALNT0396325,HSALNT0396326,HSALNT0396327,HSALNT0396328,HSALNT0396329,HSALNT0396330,HSALNT0396331,HSALNT0396332,HSALNT0396333,HSALNT0396334,HSALNT0396335,HSALNT0396411,HSALNT0396412,HSALNT0396413,HSALNT0396414,HSALNT0396415,HSALNT0396416,HSALNT0396417,HSALNT0396418",Y,NA,Human,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-26a,RNA-RNA,NA,QRT-PCR;Luciferase reporter assay,NA,Evading apoptosis;Cancer proliferation;Apoptosis;Insensitivity to antigrowth signals,NA,ceRNA,NA,NA,"LncRNA uca1 sponges mir-26a to regulate the migration and proliferation of vascular smooth muscle cells.This study reveals that lncRNA uca1 act as an endogenous sponge of mir-26a and downregulates mir-26a expression levels,and thereby relieving the inhibition of its target gene pten and alleviates vsmcs proliferation against atherosclerosis.LncRNA uca1 sponges mir-26a to regulate the migration and proliferation of vascular smooth muscle cells.",29908280
XIST,NCRNA00001;DXS1089;swd66;LINC00001;DXS399E,Xq13.2,HSALNG0138602,"HSALNT0283650,HSALNT0283651,HSALNT0283652,HSALNT0283654,HSALNT0283656,HSALNT0283657,HSALNT0283658,HSALNT0283659,HSALNT0283660,HSALNT0283661,HSALNT0283662,HSALNT0283663,HSALNT0283664,HSALNT0289343,HSALNT0407868,HSALNT0407869,HSALNT0407870,HSALNT0407871,HSALNT0407872,HSALNT0407873,HSALNT0407874,HSALNT0407875,HSALNT0407876,HSALNT0407877,HSALNT0407878,HSALNT0407879,HSALNT0407880,HSALNT0407881,HSALNT0407882,HSALNT0407883,HSALNT0407884,HSALNT0407885,HSALNT0407886,HSALNT0407887,HSALNT0407888,HSALNT0407889,HSALNT0407890,HSALNT0407891,HSALNT0407892,HSALNT0407893,HSALNT0407894,HSALNT0407895,HSALNT0407896,HSALNT0407897,HSALNT0407898,HSALNT0407899,HSALNT0407900,HSALNT0407901,HSALNT0407902,HSALNT0407903,HSALNT0407904,HSALNT0407905,HSALNT0407906,HSALNT0407907,HSALNT0407908,HSALNT0407909,HSALNT0407910,HSALNT0407911,HSALNT0407912,HSALNT0407913,HSALNT0407914,HSALNT0407915,HSALNT0407916,HSALNT0407917,HSALNT0407918,HSALNT0407919,HSALNT0407920,HSALNT0407921",Y,NA,Eutherian (placental) mammal,Disease,atherosclerosis,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,NOD2,NA,Promote,Q-RCR;Luciferase reporter assay,NA,Cell injury,NA,ceRNA,NA,NA,Further experiments identified xist regulated the expression of nucleotide-binding oligomerization domain 2 (nod2) by sponging mir-320.,29902461
XIST,,,,,,NA,,,Atherosclerosis,VSMC,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-539-5p,RNA-RNA,Inhibit,Luciferase reporter assay,NA,Invasion;Migration,NA,ceRNA,NA,NA,,35028010
XIST,,,,,,NA,,Disease,Atherosclerosis,HVSMCs,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-761,RNA-RNA,Inhibit,Luciferase reporter assay,NA,Migration;Proliferation,NA,NA,NA,NA,,34595819
